<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1388">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392089</url>
  </required_header>
  <id_info>
    <org_study_id>H-20027818</org_study_id>
    <nct_id>NCT04392089</nct_id>
  </id_info>
  <brief_title>Effects of Cardiovascular and Pulmonary Optimization on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS</brief_title>
  <acronym>NIRS-COV</acronym>
  <official_title>Effects of Cardiovascular and Pulmonary Optimisation on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to examine whether cerebral oxygenation could be a more
      useful parameter than peripheral oxygen saturation to guide clinical titration of permissive
      hypoxemia in COVID-19 ARDS patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mechanical ventilation is the cornerstone of supportive management for most ARDS patients to
      prevent life-threatening hypoxemia. Arterial oxygenation can be improved via ventilator by
      increasing fractional inspired oxygen (FiO2) and/or increasing mean airway pressure. When
      treating mechanically ventilated ARDS patients, the benefit of improved arterial oxygenation
      must be balanced against the potential risk of ventilator-induced lung injury (VILI), oxygen
      toxicity occurring with high FiO2 and development of right heart failure.

      Arterial oxygen saturation target of 88-95 % and partial oxygen pressure (PaO2) target of
      7.3-10.6 are advocated in the management of patients with ARDS. Surprisingly little
      randomized evidence exists to support these values and current recommendations are thus
      arbitrary and largely based on normal physiologic values.

      Given the lack of evidence of strategies in oxygenating critically ill patients to an oxygen
      saturation and partial oxygen pressure that is generally accepted to be 'normal,' permissive
      hypoxemia may offer an alternative that has the potential to improve patient outcomes by
      avoiding unnecessary harm. Permissive hypoxemia is a concept in which a lower level of
      arterial oxygenation than usual is accepted in order to avoid the potentially detrimental
      effects of high fractional inspired oxygen and invasive mechanical ventilation with high
      pressures, while maintaining adequate oxygen delivery by optimizing cardiac output.

      Pulse oximetry is a simple, non-invasive and universally used method to monitor peripheral
      oxygen saturation of hemoglobin in a variety of clinical settings. Pulse oximetry depends on
      pulsatile blood flow and only measures the oxyhemoglobin in arterial blood as it leaves the
      heart. However, this measure does not provide information regarding organ or tissue
      oxygenation, which reflects the important local balance between oxygen supply and demand.

      Near-infrared spectroscopy (NIRS) allows for continuous measurement of regional tissue
      oxygenation which reflects perfusion status and enables clinicians to directly monitor
      fluctuations in real time. NIRS reflects the balance of oxygen that is delivered minus what
      is extracted at tissue level and is an indicator of the tissue oxygen uptake.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in cerebral oxygenation (ScO2) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization: Step 0 = Baseline, Step 1 = Derecruitment, Step 2 = Recruitment, Step 3 = Norepinephrine challenge, Step 4 = FiO2 increase, Step 5 = FiO2 decrease, Step 6 = Baseline 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in systolic arterial pressure (SAP) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mean arterial pressure (MAP) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in heart rate (HR) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in stroke volume (SV) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cardiac output (CO) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pH during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PaO2 during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PaCO2 during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in arterial saturation (SaO2) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PvO2 during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PvCO2 during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lacatate during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and systemic arterial pressure (SAP) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and mean arterial pressure (MAP) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and stroke volume (SV) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and heart rate (HR) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and cardiac output (CO) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and pH during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and PaO2 during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and PaCO2 during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and arterial saturation (SaO2) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and PvO2 during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and PvCO2 during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and lactate during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between cerebral oxygenation (ScO2) and muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization</measure>
    <time_frame>1 hour</time_frame>
    <description>Cardiovascular and pulmonary optimization as described above</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>COVID-19</condition>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>COVID-19</arm_group_label>
    <description>Mechanically ventilated COVID-19 patients with severe ARDS included within 3 days from time of intubation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Masimo, LidCO</intervention_name>
    <description>Near-infrared spectroscopy (NIRS), pulse oxymetry (saturation), continous hemoglobine, peripheral perfusion index (PPI) as measured with Massimo
Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), stroke volume (SV), heart rate (HR), cardiac output (CO), systemic vascular resistance (SVR) as measured with LiDCO</description>
    <arm_group_label>COVID-19</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Mechanically ventilated COVID-19 patients with severe ARDS included within 3 days from time
        of intubation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years

          -  Verified COVID-19 infection (throat swab or tracheal aspirate positive for SARS-CoV-2)

          -  Severe ARDS according to Berlin definition

          -  Ventilator settings: Controlled IPPV, FiO2 &gt; 0.70, PEEP &gt; 10

          -  Norepinephrine infusion

          -  SVV &lt; 10% measured by LiDCO

          -  RASS - 5

        Exclusion Criteria:

          -  Any of the following contraindications to lung recruitment: pneumothorax, patients on
             ventilator &gt; 1 week

          -  Patients with dark pigmented skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ana-Marija Hristovska, MD, Ph.d.-student</last_name>
    <phone>+4538625532</phone>
    <email>ana-marija.hristovska.02@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana-Marija Hristovska, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Ana-Marija Hristovska</investigator_full_name>
    <investigator_title>MD, Ph.d-student</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>ARDS</keyword>
  <keyword>NIRS</keyword>
  <keyword>Saturation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

